1. Safety of endoscopic ultrasound-guided ethanol ablation for pancreatic cystic lesions: A single-center experience of 214 patients.
- Author
-
Choi JH, Lee SH, Choi YH, You MS, Shin BS, Paik WH, Ryu JK, and Kim YT
- Subjects
- Abdominal Pain etiology, Adult, Aged, Databases, Factual, Ethanol adverse effects, Female, Humans, Male, Middle Aged, Neoplasms, Cystic, Mucinous, and Serous diagnostic imaging, Pain, Postoperative etiology, Pancreatic Cyst diagnostic imaging, Pancreatic Intraductal Neoplasms diagnostic imaging, Pancreatic Neoplasms diagnostic imaging, Pancreatic Pseudocyst diagnostic imaging, Pancreatitis etiology, Patient Safety, Retrospective Studies, Risk Assessment, Risk Factors, Seoul, Treatment Outcome, Ablation Techniques adverse effects, Ethanol administration & dosage, Neoplasms, Cystic, Mucinous, and Serous surgery, Pancreatic Cyst surgery, Pancreatic Intraductal Neoplasms surgery, Pancreatic Neoplasms surgery, Pancreatic Pseudocyst surgery, Ultrasonography, Interventional
- Abstract
Background: Endoscopic ultrasound-guided ethanol ablation (EUS-EA) for pancreatic cystic lesions (PCLs) has been used in recent years as a feasible treatment modality for low malignant probability PCLs or patients considered high-risk for surgery. The present study aimed to confirm the safety of EUS-EA and to find predictive factors for adverse event (AE)., Methods: A retrospective review was performed from the prospectively maintained database of patients who underwent EUS-EA for PCLs from June 2006 to April 2018 at Seoul National University Hospital. The primary outcomes of the study were the rates of AEs and severe AEs by EUS-EA. The secondary outcome was the predictive factors of AEs including acute pancreatitis and abdominal pain., Results: A total of 214 patients were evaluated and the diagnoses of PCLs according to cystic fluid analysis and clinical features were as follows: serous cystic neoplasm (32.2%), mucinous cystic neoplasm (26.6%), branch duct type intraductal papillary mucinous neoplasm (BD-IPMN) (29.4%), and pseudocyst (11.7%). Three patients (1.4%) experienced severe AEs. Overall, AEs occurred in 71 (33.2%) patients. BD-IPMN (OR: 2.87; 95% CI: 1.05-7.84; P = 0.040), multilocular cysts (OR: 3.59; 95% CI: 1.09-11.85; P = 0.036), suspected ethanol leakage during procedure (OR: 10.68; 95% CI: 1.98-57.53; P = 0.006), and sticky cystic fluid (OR: 3.83; 95% CI: 1.20-12.24; P = 0.024) were predictive factors for post-procedural acute pancreatitis. PCLs of uncinate process (OR: 2.99; 95% CI: 1.22-7.35; P = 0.017) and PCLs with exophytic portion (OR: 3.70; 95% CI: 1.96-7.01; P < 0.001) were predictive factors for post-procedural abdominal pain., Conclusions: EUS-EA is a safe procedure with a very low rate of severe AEs. It seems possible to predict the AEs according to the features of the procedure and PCLs., (Copyright © 2019. Published by Elsevier B.V.)
- Published
- 2019
- Full Text
- View/download PDF